Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The need for new antibiotics
3. Decrease in number of new classes of antibiotics
4. Why are so few antibiotics reaching the market?
5. Companies leave the antibiotic research arena
6. Targets
7. Targeting bacterial molecules (genomics)
8. Identifying a bacteria-specific essential gene
9. Inhibition of essential gene product activity
10. Kill of bacteria by inhibitor
11. Problems with the genomic approach
12. Bacteriophages
13. Bacteriophage therapy
14. Problems with bacteriophage therapy
15. Targeting whole bacteria
16. Multiplying bacteria as a target
17. Non-culturable bacteria as a target
18. Non-multiplying bacteria as a target
19. Diseases with non-multiplying persistent bacteria
20. Bacterial endocarditis
21. Catheter infections (biofilms)
22. Prosthesis infections (biofilms)
23. Antibiotics and non-multiplying organisms
24. Consequences of non-multiplying bacteria survival
25. Methods for new antibiotics
26. Helperby therapeutics
27. Potential advantages of new antibiotics
28. Non-multiplying bacteria - obstacles
29. Many different subpopulations
30. Fewer molecular targets
31. Low penetration, high efflux
32. High local concentration of bacteria
33. Standardisation
34. Minimum stationary-cidal concentration
35. Minimum dormicidal concentration
36. Conclusion

Topics Covered

• Urgent need for new antibiotics
• Why are so few antibiotics reaching the market
• Pharmaceutical companies leaving the research arena
• Targets
• Bacterial molecules (genomics)
• Problems with the genomic approach
• Bacteriophage
• Treatments and problems with bacteriophages
• Whole bacteria
• Conventional multiplying bacteria
• Non-culturable bacteria
• Non-multiplying bacteria
• Tuberculosis, bacterial endocarditis, catheter infections and prosthesis infections
• Ways of making new antibiotics against whole live bacteria
• Potential advantages and problems of making new antibiotics which kill non-multiplying and multiplying bacteria
• Standardization

Links

Series:

• Antibiotic Resistance

Categories:

• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on December 31, 2009

Financial Disclosures

• Prof. Anthony Coates has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.